


Amendments To The Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

In the Claims:

What is claimed is:

1. (Original) A compound of formula (I):



wherein:

R¹ represents hydrogen, -C₁₋₆ alkyl, -C₁₋₆ alkoxy, -C₃₋₈ cycloalkyl, -C₁₋₆ alkyl-C₃₋₈ cycloalkyl, aryl, heterocyclyl, heteroaryl, -C₁₋₆ alkyl-aryl, -C₁₋₆ alkyl-heteroaryl, -C₁₋₆ alkyl-heterocyclyl, -aryl-aryl, -aryl-heteroaryl, -aryl-heterocyclyl, -heteroaryl-aryl, -heteroaryl-heteroaryl, -heteroaryl-heterocyclyl, -heterocyclyl-aryl, -heterocyclyl-heteroaryl, -heterocyclyl-heterocyclyl,

wherein R¹ may be optionally substituted by one or more substituents which may be the same or different, and which are selected from the group consisting of halogen, hydroxy, COOR¹⁵, cyano, -C₁₋₆ alkyl-cyano, nitro, oxo, trifluoromethyl, trifluoromethoxy, fluoromethoxy, difluoromethoxy, C₁₋₆ alkyl (optionally substituted by a COOR¹⁵ group), C₂₋₆ alkenyl (optionally substituted by a COOR¹⁵ group), C₂₋₆ alkynyl (optionally substituted by a COOR¹⁵ group), C₁₋₆ alkoxy (optionally substituted by a COOR¹⁵ group), pentafluoroethyl, C₁₋₆ alkoxy, C₂₋₆ alkenoxy, aryl, arylC₁₋₆ alkyl, -CO-aryl (optionally substituted by a halogen atom), -CO-heteroaryl, -C₁₋₆ alkyl-CO-aryl, arylC₁₋₆ alkoxy, C₁₋₆ alkylthio, C₁₋₆ alkoxyC₁₋₆ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkylC₁₋₆ alkoxy, C₁₋₆ alkoxy carbonyl, C₁₋₆ alkylsulfonyl, C₁₋₆ alkylsulfinyl, C₁₋₆ alkylsulfonyloxy, C₁₋₆ alkylsulfonylC₁₋₆ alkyl, sulfonyl, arylsulfonyl, arylsulfonyloxy, arylsulfonylC₁₋₆ alkyl, aryloxy, C₁₋₆ alkylsulfonamido, C₁₋₆ alkylamido, C₁₋₆ alkylsulfonamidoC₁₋₆ alkyl, C₁₋₆ alkylamidoC₁₋₆ alkyl, arylsulfonamido, arylcarboxamido, arylsulfonamidoC₁₋₆ alkyl, arylcarboxamidoC₁₋₆ alkyl, aroyl, aroylC₁₋₆ alkyl, arylC₁₋₆ alkanoyl, or a group -COR¹⁵, -NR¹⁵R¹⁶, -CONR¹⁵R¹⁶, -NR¹⁵COR¹⁶, -NR¹⁵SO₂R¹⁶ or -SO₂NR¹⁵R¹⁶, wherein R¹⁵ and R¹⁶ independently represent hydrogen, C₁₋₆ alkyl or C₃₋₈ cycloalkyl or together may be fused to form a 5- to 7- membered non-aromatic heterocyclic ring optionally interrupted by an O or S atom and optionally substituted by a halogen, C₁₋₆ alkyl or -C₁₋₆ alkylC₁₋₆ alkoxy group;

Z represents a bond, CO, -CON(R¹⁰)- or SO₂, such that when R¹ represents hydrogen, Z represents CONR¹⁰;

p is 1 or 2;


m, n and r independently represent 0, 1 or 2;

R² represents halogen, C₁₋₆ alkyl, C₁₋₆ alkoxy, cyano, amino or trifluoromethyl, such that when n represents 2, two R² groups may instead be linked to form a phenyl ring;

R⁴ represents C₁₋₆ alkyl, such that when r represents 2, two R⁴ groups may instead be linked to form a CH₂, (CH₂)₂ or (CH₂)₃ group;

R¹⁰ represents hydrogen or C₁₋₆ alkyl, or R¹⁰, together with R¹ forms a heterocyclic group;

R³ represents -(CH₂)_q-NR¹¹R¹² or a group of formula (i):



wherein q is 2, 3 or 4;

R¹¹ and R¹² independently represent C₁₋₆ alkyl or C₃₋₈ cycloalkyl or together with the nitrogen atom to which they are attached represent an N-linked nitrogen containing heterocyclyl group optionally substituted by one or more R¹⁷ groups;

R¹³ represents hydrogen, C₁₋₆ alkyl, -C₁₋₆ alkyl-C₁₋₆ alkoxy, C₃₋₈ cycloalkyl, -C₁₋₆ alkyl-C₃₋₈ cycloalkyl, -C₁₋₆ alkyl-aryl or heterocyclyl;

R¹⁴ and R¹⁷ independently represent halogen, C₁₋₆ alkyl, haloalkyl, OH, diC₁₋₆ alkylamino, C₁₋₆ alkoxy or heterocyclyl;

f and k independently represent 0, 1 or 2;

g is 0, 1 or 2 and h is 0, 1, 2 or 3, such that g and h cannot both be 0;

with the proviso that when m represents 1, n and r both represent 0 and R³ represents -(CH₂)₃-N-piperidine or -(CH₂)₃-N(ethyl)₂, R¹-Z represents a group other than methyl, -CO-O-C(CH₃)₃ or benzyl;

and with the proviso that when m, n and r all represent 0, p represents 1, R³ represents -(CH₂)₃-N-pyrrolidine or -(CH₂)₃-N-piperidine, R¹ represents benzyl, Z represents a group other than a bond;

and with the proviso that when m, n and r all represent 0, p represents 1, R³ represents -(CH₂)₃-N-piperidine, R¹ represents isopropyl, Z represents a group other than a bond;

and with the proviso that when m represents 1, n and r both represent 0, p represents 1, R³ represents -(CH₂)₃-N-piperidine, R¹ represents methyl, isopropyl, aryl or benzyl, Z represents a group other than a bond;

and with the proviso that when m and n both represent 0, R³ represents -(CH₂)₃-N(ethyl)₂, p represents 1, r represents 2 and R¹ and R⁴ both represent methyl, Z represents a group other than a bond;

or a pharmaceutically acceptable salt thereof.

2. (Original) A compound according to claim 1 which is a compound of formula E1-E503 or a pharmaceutically acceptable salt thereof.

3. (Currently Amended) A pharmaceutical composition which comprises the compound of ~~formula (I) as defined in claim 1 or claim 2~~ or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or excipient.
4. – 6. (Cancelled)
7. (Currently Amended) A method of treatment of neurological diseases or inflammatory diseases of the upper respiratory tract which comprises administering to a host in need thereof an effective amount of a compound of ~~formula (I) as defined in claim 1 or claim 2~~ or a pharmaceutically acceptable salt thereof.
8. (Currently Amended) A pharmaceutical composition for ~~use in~~ the treatment of neurological diseases or inflammatory diseases of the upper respiratory tract which comprises the compound of ~~formula (I) as defined in claim 1 or claim 2~~ or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
9. (New) A pharmaceutical composition which comprises the compound of claim 2 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or excipient.
10. (New) A pharmaceutical composition for the treatment of neurological diseases or inflammatory diseases of the upper respiratory tract which comprises the compound of claim 2 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
11. (New) A method of treatment of neurological diseases or inflammatory diseases of the upper respiratory tract which comprises administering to a host in need thereof an effective amount of a compound of claim 2 or a pharmaceutically acceptable salt thereof.